FDA
-
-
-
-
-
-
-
Cyclacel Pharma (CYCC) Reports Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
-
-
-
-
-
-
-
Cyclacel Pharma (CYCC) Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at EORTC-NCI-AACR
-
-
-
-
-
-
-
Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results
-
-
-
-
-
-
-
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-
-
-
-
-
-
-
Cyclacel Pharma (CYCC) Pivotal Phase 3 SEAMLESS Study in Elderly Patients With AML Doesn't Meet Primary Endpoint
-
-
322,966 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

